PureTech Health plc (PRTC)
US — Healthcare Sector
Automate Your Wheel Strategy on PRTC
With Tiblio's Option Bot, you can configure your own wheel strategy including PRTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRTC
- Rev/Share 0.0017
- Book/Share 1.5128
- PB 1.1639
- Debt/Equity 0.0539
- CurrentRatio 9.3326
- ROIC -0.2776
- MktCap 429938328.0
- FreeCF/Share -0.4455
- PFCF -3.579
- PE -5.8763
- Debt/Assets 0.0371
- DivYield 0
- ROE -0.2249
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PRTC | Leerink Partners | -- | Outperform | $58 | $45 | Sept. 9, 2024 |
News
PureTech Health: Results of Annual General Meeting
PRTC
Published: June 16, 2025 by: Business Wire
Sentiment: Neutral
Published: June 16, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
Read More
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
PRTC
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).
Read More
PureTech Announces Annual Results for Year Ended December 31, 2024
PRTC
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.
Read More
PureTech Health plc Statement Regarding Press Speculation
PRTC
Published: April 07, 2025 by: Business Wire
Sentiment: Neutral
Published: April 07, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Statement regarding press speculation.
Read More
About PureTech Health plc (PRTC)
- IPO Date 2020-11-16
- Website https://www.puretechhealth.com
- Industry Biotechnology
- CEO Dr. Bharatt M. Chowrira J.D., Ph.D.
- Employees 80
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.